AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22297415 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week stretching program (right calf muscle stretched 4 times for 30 seconds, 3 days per week)
Number of subjects: 25
Study 22297415 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study 20657532 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical heparin spray (added to antiplatelet therapy)
Number of subjects: 0
Study 20657532 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy only
Number of subjects: 0
Study 18830087 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to Mediterranean-type diet (MeDiet)
Number of subjects: 3204
Study 15967849 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 37939
Study 15967849 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 37939
Study 15967849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 37939
Study 15967849 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 37939
Study 15967849 — intervention group
Group type: COMPARATOR
Intervention: Control group (ACE I/D genotype)
Number of subjects: 37939
Study 12581487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingested IFN-alpha in type 1 diabetes
Number of subjects: 0
Study 12581487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingested IFN-alpha in rheumatoid arthritis
Number of subjects: 0
Study 12581487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingested IFN-alpha in multiple sclerosis
Number of subjects: 0
Study 12581487 — intervention group
Group type: COMPARATOR
Intervention: Ingested IFN-alpha (10,000 IU) in multiple sclerosis
Number of subjects: 0
Study 11126694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0
Study 11126694 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol patch
Number of subjects: 0
Study 11126694 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate
Number of subjects: 0
Study 9091475 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN‐gamma) 100 micrograms subcutaneously for 5 consecutive days followed by 100 micrograms once weekly for 4 weeks
Number of subjects: 24
Study 9091475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7690364 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 300 mg im, each week for 6 weeks
Number of subjects: 11
Study 7690364 — intervention group
Group type: COMPARATOR
Intervention: Nandrolone decanoate (ND) 300 mg im, each week for 6 weeks
Number of subjects: 11
Study 7690364 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE)
Number of subjects: 11
Study 7690364 — intervention group
Group type: COMPARATOR
Intervention: Nandrolone decanoate (ND)
Number of subjects: 11
Study 3732048 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (A) and Cyclophosphamide (C)
Number of subjects: 300
Study 3732048 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (A) and Cis-platin
Number of subjects: 300
Study 3732048 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing scheme (A/P-V/C-HD-MTX)
Number of subjects: 300
Study 30324422 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III formulation with reduced SLS content, administered following a low-fat meal
Number of subjects: 0
Study 30324422 — intervention group
Group type: COMPARATOR
Intervention: Phase I/II formulation, administered under the same conditions
Number of subjects: 0
Study 26684776 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral implantation
Number of subjects: 57
Study 26684776 — intervention group
Group type: COMPARATOR
Intervention: Traditional sequential electrode implantation
Number of subjects: 57
Study 24313246 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS; a cognitive‐behavioral intervention)
Number of subjects: 141
Study 24313246 — intervention group
Group type: COMPARATOR
Intervention: Women's Health Education (WHE; a control group intervention)
Number of subjects: 141
Study 22237795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural coping skills (CBCS); specific dosage and duration not mentioned.
Number of subjects: 0
Study 22237795 — intervention group
Group type: COMPARATOR
Intervention: Counselling sessions; specific details not mentioned.
Number of subjects: 0
Study 20529805 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR)
Number of subjects: 0
Study 20529805 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 0
Study 18343253 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical amethocaine gel 4%
Number of subjects: 110
Study 18343253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 18343253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' assessment
Number of subjects: 110
Study 15809408 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications (paroxetine, up to 50 mg daily)
Number of subjects: 240
Study 15809408 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 240
Study 15809408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 12206277 — intervention group
Group type: EXPERIMENTAL
Intervention: 1st language (either Filipino or English)
Number of subjects: 0
Study 12206277 — intervention group
Group type: COMPARATOR
Intervention: 2nd language (either Filipino or English)
Number of subjects: 0
Study 10233784 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent grafts (n = 409)
Number of subjects: 746
Study 10233784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontreated asymptomatic occlusions (n = 32)
Number of subjects: 746
Study 10233784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontreated symptomatic occlusions (n = 65)
Number of subjects: 746
Study 10233784 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent revascularizations (n = 194)
Number of subjects: 746
Study 10233784 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful revascularization
Number of subjects: 746
Study 10233784 — intervention group
Group type: EXPERIMENTAL
Intervention: Amputation (n = 36)
Number of subjects: 746
Study 10233784 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed secondary revascularizations followed by secondary amputation (n = 38)
Number of subjects: 746
Study 10233784 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol score
Number of subjects: 746
Study 8706447 — intervention group
Group type: EXPERIMENTAL
Intervention: MAK 195F (anti-TNF antibody) at 0.1 mg/kg
Number of subjects: 122
Study 8706447 — intervention group
Group type: EXPERIMENTAL
Intervention: MAK 195F (anti-TNF antibody) at 0.3 mg/kg
Number of subjects: 122
Study 8706447 — intervention group
Group type: EXPERIMENTAL
Intervention: MAK 195F (anti-TNF antibody) at 1.0 mg/kg
Number of subjects: 122
Study 8706447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 1758188 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.12 mg/kg
Number of subjects: 124
Study 1758188 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.2 mg/kg
Number of subjects: 124
Study 1758188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 31640924 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC+F (physical activity counselling session plus provision of a Fitbit)
Number of subjects: 52
Study 31640924 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC+F
Number of subjects: 52
Study 31640924 — intervention group
Group type: COMPARATOR
Intervention: PAC
Number of subjects: 52
Study 31150399 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE) during three brief public speaking scenarios
Number of subjects: 19
Study 31150399 — intervention group
Group type: EXPERIMENTAL
Intervention: Second scenario of VRE
Number of subjects: 19
Study 28168203 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 39
Study 28168203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 25835751 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR (solubilized 17β‐estradiol and natural progesterone)
Number of subjects: 0
Study 25835751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25835751 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-001HR
Number of subjects: 0
Study 24034909 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA (neurally adjusted ventilatory assist)
Number of subjects: 10
Study 24034909 — intervention group
Group type: COMPARATOR
Intervention: SIMV (synchronized intermittent mandatory ventilation)
Number of subjects: 10
Study 21357860 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial-dose-doxycycline (SDD)
Number of subjects: 128
Study 19360538 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use onset (alcohol, cigarettes, dagga, inhalants)
Number of subjects: 1118
Study 19360538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime cigarette use
Number of subjects: 1118
Study 19360538 — intervention group
Group type: EXPERIMENTAL
Intervention: Dagga (cannabis) and inhalant use
Number of subjects: 1118
Study 18173524 — intervention group
Group type: EXPERIMENTAL
Intervention: NailQoL instrument
Number of subjects: 402
Study 15086197 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal drainage after liver resection
Number of subjects: 0
Study 15086197 — intervention group
Group type: COMPARATOR
Intervention: Non-drainage group
Number of subjects: 0
Study 11469522 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 228
Study 11469522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 228
Study 11469522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 9883763 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 21
Study 9883763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 21
Study 9883763 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 21
Study 8032701 — intervention group
Group type: EXPERIMENTAL
Intervention: Different anti-emetics used in the trials
Number of subjects: 582
Study 8032701 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens
Number of subjects: 582
Study 2915293 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg IVIG (Gamimune)
Number of subjects: 16
Study 2915293 — intervention group
Group type: COMPARATOR
Intervention: 20% dextrose (control)
Number of subjects: 16
Study 977755 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial highly structured leader role followed by a relatively unstructured leader role
Number of subjects: 0
Study 977755 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured throughout
Number of subjects: 0
Study 977755 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured throughout
Number of subjects: 0
Study 977755 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured to structured
Number of subjects: 0
Study 977755 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured to unstructured
Number of subjects: 0
Study 977755 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0
Study 30797491 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS‐GS guided bronchoscopy biopsy
Number of subjects: 1010
Study 30797491 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EBUS‐GS and virtual bronchoscopic navigation (VBN)
Number of subjects: 1010
Study 30797491 — intervention group
Group type: COMPARATOR
Intervention: Traditional, non‐guided bronchoscopy biopsy (NGB group)
Number of subjects: 1010
Study 30797491 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (EBUS‐GS with VBN)
Number of subjects: 1010
Study 30797491 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS group
Number of subjects: 1010
Study 30797491 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS‐GS and combined groups
Number of subjects: 1010
Study 30797491 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral pulmonary lesions (PPLs) >20 mm in diameter
Number of subjects: 1010
Study 28169019 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 570
Study 28169019 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk
Number of subjects: 570
Study 28169019 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy mediation
Number of subjects: 570
Study 25564782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial suction technique
Number of subjects: 58
Study 25564782 — intervention group
Group type: COMPARATOR
Intervention: Disconnection method
Number of subjects: 58
Study 23425338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency spinal cord stimulation (HFSCS)
Number of subjects: 40
Study 23425338 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study 23425338 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HFSCS and sham
Number of subjects: 40
Study 21526380 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior decompression and fusion (group A, n = 27)
Number of subjects: 56
Study 21526380 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior laminectomy (group P, n = 29)
Number of subjects: 56
Study 21526380 — intervention group
Group type: COMPARATOR
Intervention: Group H (with hyperintensity on MRI, n = 31)
Number of subjects: 56
Study 21526380 — intervention group
Group type: COMPARATOR
Intervention: Group L (with hypointensity on MRI, n = 19)
Number of subjects: 56
Study 21526380 — intervention group
Group type: EXPERIMENTAL
Intervention: Group N (no signal on MRI, n = 25)
Number of subjects: 56
Study 18093738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain training intervention
Number of subjects: 93
Study 17162166 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive technique
Number of subjects: 70
Study 17162166 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 70
Study 12899105 — intervention group
Group type: EXPERIMENTAL
Intervention: School Functioning Index (SFI) developed for middle schools; specific intervention details not provided.
Number of subjects: 16
Study 10731459 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (n = 416)
Number of subjects: 878
Study 10731459 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 462)
Number of subjects: 878
Study 9121638 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) using 'Elektronika‐2M' apparatus with a current of 45 microA for 10‐20 min, with courses consisting of 10‐12 treatments.
Number of subjects: 34
Study 9121638 — intervention group
Group type: COMPARATOR
Intervention: Standard methods of treatment (novocaine blockade, analgesics, etc.)
Number of subjects: 34
Study 1389525 — intervention group
Group type: COMPARATOR
Intervention: Extended field radiotherapy (RT)
Number of subjects: 89
Study 1389525 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy
Number of subjects: 89
Study 4053732 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 0
Study 4053732 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0
Study 31564217 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion Break
Number of subjects: 129
Study 31564217 — intervention group
Group type: COMPARATOR
Intervention: Time Management Control Group
Number of subjects: 129
Study 31564217 — intervention group
Group type: COMPARATOR
Intervention: No-Induction Control Group
Number of subjects: 129
Study 29329493 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam IV 60 mg
Number of subjects: 230
Study 29329493 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam IV 30 mg
Number of subjects: 230
Study 29329493 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam IV 15 mg
Number of subjects: 230
Study 29329493 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 230
Study 29329493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 27039291 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg monthly)
Number of subjects: 218
Study 27039291 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe (10 mg daily)
Number of subjects: 218
Study 24763888 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia with hyperbaric bupivacaine (2 ml, 0.5%)
Number of subjects: 50
Study 24763888 — intervention group
Group type: COMPARATOR
Intervention: L1 paravertebral block combined with psoas compartment block and sciatic nerve block with bupivacaine hydrochloride (total 35 ml)
Number of subjects: 50
Study 22838231 — intervention group
Group type: COMPARATOR
Intervention: Vitremer Primer (positive control)
Number of subjects: 6
Study 22838231 — intervention group
Group type: EXPERIMENTAL
Intervention: 32% phosphoric acid
Number of subjects: 6
Study 22838231 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% polyacrylic acid
Number of subjects: 6
Study 22838231 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐etch adhesive (Prompt L Pop)
Number of subjects: 6
Study 22838231 — intervention group
Group type: EXPERIMENTAL
Intervention: etch & rinse adhesive (Prime & Bond NT)
Number of subjects: 6
Study 22838231 — intervention group
Group type: COMPARATOR
Intervention: no surface treatment (negative control)
Number of subjects: 6
Study 20691348 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating (SL) brackets (Damon 3MX)
Number of subjects: 50
Study 20691348 — intervention group
Group type: COMPARATOR
Intervention: Conventional ligated (CL) brackets (Victory Series or Mini-Diamond)
Number of subjects: 50
Study 19025303 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication therapy (10-day course of rabeprazole, amoxicillin, and clarithromycin, followed by 20 mg of rabeprazole for 3 months)
Number of subjects: 48
Study 19025303 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (20 mg of rabeprazole for 3 months)
Number of subjects: 48
Study 15636615 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid stop
Number of subjects: 833
Study 15636615 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF stop
Number of subjects: 833
Study 15636615 — intervention group
Group type: COMPARATOR
Intervention: Control (triple therapy)
Number of subjects: 833
Study 14651431 — intervention group
Group type: EXPERIMENTAL
Intervention: MOS-HIV health survey administered at baseline and every 3 months during 1-year follow-up
Number of subjects: 185
Study 14651431 — intervention group
Group type: EXPERIMENTAL
Intervention: MOS-HIV health survey
Number of subjects: 185
Study 10965646 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral weight-control program plus parent and child problem solving
Number of subjects: 67
Study 10965646 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral weight-control program plus child problem solving
Number of subjects: 67
Study 10965646 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with no additional problem solving
Number of subjects: 67
Study 10965646 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent + child problem solving
Number of subjects: 67
Study 10965646 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (including child problem solving)
Number of subjects: 67
Study 10965646 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 67
Study 8980428 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared optoelectronic system (Perometer)
Number of subjects: 27
Study 8980428 — intervention group
Group type: COMPARATOR
Intervention: Water displacement
Number of subjects: 27
Study 8980428 — intervention group
Group type: COMPARATOR
Intervention: Disc model method
Number of subjects: 27
Study 8980428 — intervention group
Group type: COMPARATOR
Intervention: Frustrum method
Number of subjects: 27
Study 8980428 — intervention group
Group type: EXPERIMENTAL
Intervention: Perometer
Number of subjects: 27
Study 8980428 — intervention group
Group type: COMPARATOR
Intervention: Disc method
Number of subjects: 27
Study 1291328 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate toothpaste (1000 ppm MFP and 450 ppm NaF)
Number of subjects: 50
Study 3842878 — intervention group
Group type: EXPERIMENTAL
Intervention: Child life intervention from child life staff
Number of subjects: 3
Study 3842878 — intervention group
Group type: COMPARATOR
Intervention: Control A (pediatric hospital)
Number of subjects: 3
Study 3842878 — intervention group
Group type: COMPARATOR
Intervention: Control B (general hospital)
Number of subjects: 3
Study 31687764 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of lesions
Number of subjects: 43
Study 31687764 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability of lesions
Number of subjects: 43
Study 31687764 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of lesions
Number of subjects: 43
Study 28510646 — intervention group
Group type: EXPERIMENTAL
Intervention: Switched DAPT (aspirin plus clopidogrel)
Number of subjects: 646
Study 28510646 — intervention group
Group type: COMPARATOR
Intervention: Unchanged DAPT (aspirin plus newer P2Y12 blocker)
Number of subjects: 646
Study 25728888 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri-containing lozenges
Number of subjects: 40
Study 25728888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23222534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) - 15 mg/kg to a maximum of 1000 mg IV for NDD-CKD; 200 mg IV push for HD-CKD
Number of subjects: 454
Study 23222534 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC) - treatment determined by the investigator, could include oral iron, IV iron or no iron
Number of subjects: 454
Study 23222534 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 454
Study 23222534 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 454
Study 21570146 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring with a quantitative urine glucose meter (Group A)
Number of subjects: 108